JCI Pharmaceutical

JCR Pharmaceuticals is a Japanese biopharmaceutical company specializing in the development of treatments for rare diseases, particularly lysosomal storage diseases (LSDs). The company is best known for its proprietary J-Brain Cargo technology, a blood-brain barrier (BBB) penetration platform that enables the delivery of biotherapeutics into the central nervous system. Their lead product, Izcargo (pabinafusp alfa), was the first BBB-penetrating enzyme replacement therapy approved for Hunter syndrome. JCR maintains a robust pipeline of enzyme replacement therapies and regenerative medicine products, often collaborating with global partners like Takeda and Denali Therapeutics. The company also possesses significant manufacturing capabilities, having partnered with AstraZeneca to produce COVID-19 vaccines in Japan.